Objectively, there isn't anything disappointing in these...

Objectively, there isn't anything disappointing in these results. Nor is there anything surprising. They are pretty much in line with the more rational consensus of what has been discussed here for the past few months.

(1) Viral loads reduced by 2 log , 96% for BIT225 vs 90% for the control. Is this statistically significant? Hard to tell when the control gives you 90% anyway until the rigorous statistical tests are done.

(2) SVR12 is the key. If there is no rebound in the virus levels at 12 weeks post treatment that will definitely be something. Yet more waiting unfortunately.

(3) Is there significant difference on the G3 cohort? That will also be something.

In the meantime - it's the same old same old, buy on rumor, sell on fact playing out on the market.